Please ensure Javascript is enabled for purposes of website accessibility

Why Synergy Pharmaceuticals Is Spiking 13% Today

By Todd Campbell - May 16, 2016 at 11:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are cheering ahead of an upcoming presentation for its lead product candidate at a key industry conference.

Image source: Synergy Pharmaceuticals.

What: After announcing that it will present information on the efficacy and safety of its lead product candidate plecanatide at the Digestive Disease Week 2016 in San Diego, May 21-24, shares of Synergy Pharmaceuticals, (NASDAQ: SGYP) were soaring 13.5% higher at 11:00 a.m. ET today.

So what: The conference will give the company an opportunity to show doctors data from trials evaluating plecanatide for use in patients with chronic idiopathic constipation (CIC). Previously, Synergy Pharmaceuticals reported phase 3 trial results showing that plecanatide effectively addresses CIC and that it does so with a potentially best-in-class low incidence rate of severe diarrhea. 

If its efficacy and safety profile resonate with prescribers, then plecanatide could eventually cut into sales of market leader Linzess, a drug co-marketed by Ironwood Pharmaceuticals (IRWD 2.65%) and Allergan (AGN). On May 9, Ironwood Pharmaceuticals reported that Linzess U.S. net sales increased 44% to $137 million in the first quarter compared to Q1 2015, and that Linzess is on track to exceed $1 billion in net sales by 2020.

Now what: Synergy Pharmaceuticals application for approval was accepted by the Food and Drug Administration earlier this year, and that positions the company to receive approval on plecanatide next January.

The market for constipation drugs is big and plecanatide's safety profile offers an opportunity to win away market share, but investors should remember that Synergy Pharmaceuticals owes nearly $80 million and that spending will increase ahead of commercialization. All that spending means that there's no telling when this company could turn profitable. Also, investors should remember that there's always the risk that the FDA will opt against approving plecanatide, and if that happens, then it would significantly impact the company's share price.

Overall, while the market potential for plecanatide is big enough to make this company intriguing, its balance sheet is a bit of a question mark, and given its unclear path to profitability, I'm focusing on other investment ideas.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ironwood Pharmaceuticals, Inc. Stock Quote
Ironwood Pharmaceuticals, Inc.
$11.60 (2.65%) $0.30
Allergan plc Stock Quote
Allergan plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.